胰島素生物相似藥市場規模、佔有率、成長分析（按類型、適應症、分銷管道和地區）- 產業預測，2025-2032 年

全球胰島素生物相似藥市場預計將在 2023 年達到 29 億美元，並從 2024 年的 30.8 億美元成長到 2032 年的 49.8 億美元，預測期內（2025-2032 年）的複合年成長率為 6.2%。

由於糖尿病盛行率的上升以及糖尿病研發（R&D）投入的增加，胰島素生物相似藥市場預計將顯著成長。全球範圍內對有效糖尿病管理的需求日益成長，預計將在未來幾年推動對這些產品的需求。創新胰島素生物相似藥的新臨床試驗正在進一步推動市場擴張，而原始胰島素製劑的專利到期也為市場參與者創造了新的商機。然而，挑戰仍然存在，包括嚴格的監管要求以及圍繞新生物相似藥的臨床接受度問題，這可能會阻礙長期的整體市場發展。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和資料資料
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

胰島素生物相似藥市場規模（按類型）

• 市場概況
• 速效胰島素
  • 速效胰島素類似物
  • 常規人類胰島素
• 中效胰島素
  • NPH 人類胰島素
  • 混合胰島素
• 長效胰島素

胰島素生物相似藥市場規模（依適應症分類）

• 市場概況
• 1 型糖尿病
• 2 型糖尿病

胰島素生物相似藥市場規模（按分銷管道）

• 市場概況
• 醫院藥房
• 零售藥局
• 藥局
• 網路藥局

胰島素生物相似藥市場規模及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較（2022-2024 年）

主要企業簡介

• Viatris Inc.（USA）
• Pfizer Inc.（USA）
• Sanofi SA（France）
• Eli Lilly and Company（USA）
• Novartis AG（Switzerland）
• Merck & Co., Inc.（USA）
• Boehringer Ingelheim GmbH（Germany）
• Biocon Ltd.（India）
• Samsung Bioepis（South Korea）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Fresenius Kabi AG（Germany）
• Coherus BioSciences, Inc.（USA）
• Dr. Reddy's Laboratories Ltd.（India）
• Amgen Inc.（USA）
• Celltrion Inc.（South Korea）
• Aurobindo Pharma Ltd.（India）
• Intas Pharmaceuticals Ltd.（India）
• Fujifilm Kyowa Kirin Biologics Co., Ltd.（Japan）
• Mochida Pharmaceutical Co., Ltd.（Japan）

結論和建議

Global Insulin Biosimilars Market size was valued at USD 2.9 billion in 2023 and is poised to grow from USD 3.08 billion in 2024 to USD 4.98 billion by 2032, growing at a CAGR of 6.2% during the forecast period (2025-2032).

The market for insulin biosimilars is poised for significant growth due to the rising prevalence of diabetes, coupled with increasing investments in diabetes research and development (R&D). The ongoing need for effective diabetes management globally is expected to drive demand for these products in the coming years. New clinical trials for innovative insulin biosimilars will further facilitate market expansion, supported by the impending patent expirations of original insulin products, which presents fresh opportunities for market players. However, challenges remain, including stringent regulatory requirements and issues surrounding the clinical acceptance of new biosimilars, which could hinder overall market development in the long term.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Insulin Biosimilars market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Insulin Biosimilars Market Segmental Analysis

Global Insulin Biosimilars Market is segmented by Type, Indication, Distribution Channel, and region. Based on Type, the market is segmented into Fast-acting Insulin, Intermediate-acting Insulin and Long-acting Insulin. Based on Indication, the market is segmented into Diabetes Type 1 and Diabetes Type 2. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Insulin Biosimilars Market

The Global Insulin Biosimilars market is significantly driven by the impending patent expirations of established originator insulin products. As these long-standing products become less protected, it is expected to increase the demand for innovative new biosimilars. Furthermore, the rising investment in medical research and development is anticipated to open up new avenues for manufacturers of insulin biosimilars, facilitating the introduction of advanced therapeutic options to the market. This combination of patent expirations and heightened R&D activities is poised to transform the competitive landscape, ultimately benefiting patients with more affordable and effective insulin alternatives.

Restraints in the Global Insulin Biosimilars Market

The global insulin biosimilars market faces significant constraints due to complex regulatory mandates imposed by governments and regulatory authorities. These stringent regulations create challenges for new companies aiming to develop and introduce insulin biosimilars to the market. The arduous approval processes and extensive requirements can hinder innovation and slow down the entry of novel products. As a result, many potential developers may find it daunting to navigate the regulatory landscape, ultimately limiting competition and variety within the market. This restrictive environment poses a substantial barrier to the growth and expansion of the insulin biosimilars sector on a global scale.

Market Trends of the Global Insulin Biosimilars Market

The Global Insulin Biosimilars market is witnessing a significant trend towards the adoption of biologic and biosimilar therapies for diabetes management. As patients and healthcare institutions increasingly prioritize cost-effective treatment options, the demand for high-quality insulin biosimilars is rising, presenting lucrative opportunities for suppliers. This shift is fueled by the need for affordable alternatives to traditional insulin therapies, alongside growing awareness of the efficacy and safety of biosimilars. Companies that innovate and develop novel biosimilar products in alignment with this market trend are poised to enhance their market presence and drive revenue growth in the competitive diabetes care landscape.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Insulin Biosimilars Market Size by Type: & CAGR (2025-2032)

• Market Overview
• Fast-acting Insulin
  • Rapid-acting Insulin Analogs
  • Regular Human Insulin
• Intermediate-acting Insulin
  • NPH Human Insulin
  • Pre-mixed Insulin
• Long-acting Insulin

Global Insulin Biosimilars Market Size by Indication: & CAGR (2025-2032)

• Market Overview
• Diabetes Type 1
• Diabetes Type 2

Global Insulin Biosimilars Market Size by By Distribution Channel: & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies

Global Insulin Biosimilars Market Size & CAGR (2025-2032)

• North America (Type:, Indication:, By Distribution Channel:)
  • US
  • Canada
• Europe (Type:, Indication:, By Distribution Channel:)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type:, Indication:, By Distribution Channel:)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type:, Indication:, By Distribution Channel:)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type:, Indication:, By Distribution Channel:)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Viatris Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Bioepis (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Coherus BioSciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celltrion Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intas Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujifilm Kyowa Kirin Biologics Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mochida Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations